BEPREVE (bepotastine besilate) by Bausch + Lomb is active, direct h1-receptor antagonist and an inhibitor of the release of histamine from mast cells. Approved for allergic conjunctivitis. First approved in 2009.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
BEPREVE (bepotastine besilate) is an ophthalmic solution that acts as a direct H1-receptor antagonist and mast cell stabilizer for allergic eye conditions. It is indicated for allergic conjunctivitis and related allergic/pruritic conditions affecting the eye. The drug works by blocking histamine release from mast cells and antagonizing H1 receptors to reduce allergic inflammation.
With LOE approaching and modest Part D spending, the BEPREVE brand team is likely focused on defensive strategy and cost management rather than growth expansion.
active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.
Bioequivalence Test of "Dong-a Bepotastine Besilate Tab" and "Twolion Tab"
Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis
Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses
The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
Worked on BEPREVE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moBEPREVE is generating minimal linked job postings, reflecting its mature, low-spending position and approaching LOE. Career opportunities on this brand are likely limited to small legacy teams managing decline and regulatory compliance.